FENNEC PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Recognition and Exercise
FENNEC PHARMACEUTICALS INC. (FENC) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $990.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2026-08-13
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2026-03-31 was $990.00K, a 24.06% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-09-30 was $2.22M, a 21.86% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-06-30 was $1.49M, a 61.51% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2025-03-31 was $798.00K, a 33.00% decline year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month as first filed | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month |
|---|---|---|---|---|
| 2026-03-31 | $990.00K 10-Q · filed 2026-08-13 | $1.32M 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | $2.22M 10-Q · filed 2025-11-13 | $3.71M derived: sum of 2 quarters · filed 2026-08-13 | $4.51M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.49M 10-Q · filed 2026-08-13 | $2.29M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $798.00K 10-Q · filed 2025-11-13 | $371.00K 10-Q · filed 2025-05-14 | ||
| 2024-09-30 | $1.82M 10-Q · filed 2025-11-13 | $2.75M derived: sum of 2 quarters · filed 2025-11-13 | $3.94M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $925.00K 10-Q · filed 2025-11-13 | $2.12M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $1.19M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |